Complex karyotype abnormalities in pediatric acute myeloid leukemia

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 5, 2008, Pages 3-7

  Fleishman, Ye V ^a   Sokova, O I ^a   Kirichenko, O P ^a   Konstantinova, L N ^a   Metelkova, N F ^a   Popa, A V ^a   Shneider, M M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46249121894     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Grimwade D., Walker H., Oliver F. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
2. Grimwade D., Walker H., Harrison G. et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98: 1312-1320.
3. Byrd J. C., Mrozek K., Dodge R. C. et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: results from GALB 8461. Blood 2002; 100: 4325-4336.
4. Schoch C., Kern W., Krawitz P. et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood 2001; 98: 3500.
5. Schoch C., Kern W., Schnittger S. et al. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004; 89 (9): 1082-1090.
6. Slovak M. L., Kopecku K. J., Cassileth P. A. et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia. Blood 2000; 96: 4075-4083.
7. Meschinchi S., Arcei R. J. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist 2007; 12: 341-355.
8. Schoch C., Schnlttger S., Kern W. et al. Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid leukemia. Haematologica 2003; 88: 351-352.
9. Schoch C., Kern W., Kohimann F. et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosom. Cancer 2005; 43: 227-238.
10. Schoch C., Haferlach T., Haase D. et al. Patients with de novo acute myeloid leukemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br. J. Haematol. 2001; 112: 118-126.
11. Shaffer L. G., Tommerup N., eds. ISCN-2005: An international system for human cytogenetic nomenclature. Basel: Karger; 2005.
12. Russian source
13. Kaspers G. J. L., Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005; 19: 2025-2029.
14. Heim S., Mitelman F. Cancer cytogenetics. 2-nd ed. New York: Wiley-Liss; 1995.
15. Pui C.-H., Raimondi S. C., Srivastava D. K. Prognostic factors in infants with acute myeloid leukemia. Leukemia 2000; 14: 684-687.
16. Webb D. K. H., Harrison G., Stevens R. F. et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714-1720.
17. Moorman A. V., Roman E., Willett E. V. et al. Karyotype and age in acute myeloid leukemia. Are they linked? Cancer Genet. Cytogenet. 2001; 126: 155-161.